Definiens Appoints Dr. Gerald Möller as Chairman of its Supervisory Board
Definiens AG announced that Dr. Gerald Möller, has joined the company's supervisory board as an independent member and has been appointed chairman. Following the recent financing round, Dr. Möller will guide the expansion of Definiens' current business and the development and commercialization of innovative products for clinical Digital Pathology.
Previously, Dr. Möller spent 23 years at Boehringer Mannheim in Germany, Japan and the US, where he held a number of leadership positions, including president of Decentralized Diagnostics, president of Advanced Diagnostics and Biochemicals, and CEO of Boehringer Mannheim Therapeutics. In 1995 he became CEO of the worldwide Boehringer Mannheim Group. Following the company's acquisition by Roche, Dr. Möller became head of Global Development and Strategic Marketing, Pharmaceuticals, and a member of the Executive Committee at Hoffmann LaRoche. In addition to Definiens, Dr. Möller is chairman of the board at Morphosys AG and sits on several further life sciences and diagnostics boards, including Illumina Inc., Bionostics Inc., and Vivacta Ltd. He also is chairman of the Foundation for Innovative New Diagnostics (FIND), a product development and implementation partnership financed in part by the Bill & Melinda Gates Foundation. He holds a Ph.D. in physical chemistry from the University of Kiel in Germany.
Most read news
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Celera and Collaborators Discover a Genetic Marker Associated with Severe Coronary Artery Disease - Carriers of gene variant exhibit an approximate 3-fold increased risk of disease

Cells talk at each other to specialize different functions - New concept to describe how cells specialize during development
The French biotechnology industry on the launchpad - France Biotech recommends accelerating efforts to allow takeoff - France Biotech unveils « 2004 French Biotechnology Industry Report » on December 15th in Paris
